Company intelligence / Profile preview

Third Harmonic Bio

San Francisco, California, USAthirdharmonicbio.com ↗

Ownership: Public · THRD
Development stage: Phase 1

Overview

The company has completed Phase 1 single and multiple ascending dose trials for THB335 in healthy volunteers, demonstrating dose-dependent reductions in serum tryptase (a biomarker of mast cell activation). However, the company has announced plans for liquidation and dissolution in April 2025, with stockholder approval to be sought on June 5, 2025.

Therapeutic areas: GastroenterologyPulmonologyDermatologyImmunology
Modalities: Small moleculesoral KIT inhibitors
Industry: Biotech

Drug pipeline

2 assets

THB335

1 more asset in the full pipeline.

Request access →

Financials

Market cap: $242.8M
Total revenue: $0
Enterprise value: $-25.8M

Beyond the preview

Go deeper on Third Harmonic Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Third Harmonic Bio.

Explore the full profile